Vaccine news prompts Asian share rally but signs of weakness emerge
Reuters
Published Nov 10, 2020 02:18
Updated Nov 10, 2020 06:55
By Scott Murdoch
HONG KONG (Reuters) - Asian share markets mostly rose on Tuesday as global investors applauded successful trial data for a coronavirus vaccine, although expected delays to any mass roll-out took the gloss off early gains.
European futures (STXEc1) trading during the Asian session were indicating a weaker open of at least 1.2%, while U.S. futures showed a potential fall of at least 0.5% (ESc1) after Monday's steep market gains.
The positive tone in Asian equities came after Pfizer Inc (N:PFE) said its COVID-19 vaccine, developed with German partner BioNTech SE (O:BNTX), was more than 90% effective in preventing infection, marking the first successful results from a large-scale clinical trial.
Major Asian markets soared on the vaccine news before weakening later in the session.
Japan's Nikkei 225 (N225) ended up nearly 0.3% after being 1.1% higher in early trading, touching a 29-year high.
Australia's S&P/ASX 200 (AXJO) closed 0.66% higher after trading up as much as 1.6%, while Hong Kong's Hang Seng index (HSI) was at 0.77% in the afternoon after rising 1% in early trade.
Singapore's Straits Times (STI) gained 2.94% to take the index to its highest point since June.
Despite the optimistic tone across the region, there was some weakness in China, with the CSI300 Index (CSI300) slipping 0.17%.
Analysts attributed the decline to the heavy exposure of China's indices to tech stocks, which came under pressure as investors eyed less consumer reliance on technology if a vaccine leads to an easing of movement restrictions.
MSCI's broadest index of Asia-Pacific shares outside Japan (MIAPJ0000PUS) was 0.1% higher.
"The market is looking forward to a more sustained solution to the pandemic and that is why we have seen such a sharp reaction," said Tai Hui, chief Asia market strategist at JPMorgan (NYSE:JPM) Asset Management
However, he sounded caution over the speed in which the vaccine could be implemented.
"Given more tests are needed, then the approval process. Manufacturing and distribution would mean the vaccine, if truly effective, is still months away from mass deployment,"
The equities optimism was not shared across all asset classes. Oil prices slipped in Asian trade after posting the biggest one-day percentage gain in five months.
The overnight rise prompted some traders to take profits, analysts said.
Brazil's health regulator said on Monday it had suspended clinical trials for China's Sinovac coronavirus vaccine after adverse effects had emerged.
STOCKS ROTATION
Airline, travel and tourism stocks across Asia were beneficiaries of the positive sentiment from the vaccine announcement and held their gains while the broader indices weakened in the afternoon.
Get The App
"No surprises but it's essentially a rotation ... what was bought in the last eight months is now being sold and what was sold is being bought," Citigroup (NYSE:C) global markets director Elizabeth Tian said.
Qantas Airways (AX:QAN) closed 8.3% higher to hit its highest level since March, Japan Airlines (T:9201) shot 20.6% higher and ANA Holdings (T:9202) rose 17.5%.
In Hong Kong, Cathay Pacific Airways (HK:0293) shares jumped 13%, the best since July.
"Markets will get ahead of themselves in the short term with the vaccine news but longer term it feels like it is going higher," Ord Minnett advisor John Milroy said from Sydney.
Early Tuesday, Japan's Prime Minister Yoshihide Suga instructed his cabinet to design a fresh stimulus package to help revive the nation's flagging economy to offset the ongoing effects of coronavirus..
On Wall Street, the Dow Jones Industrial Average (DJI) rose 2.95%, the S&P 500 (SPX) gained 1.17% while the Nasdaq Composite (IXIC) dropped 1.53%. E-mini futures for the S&P 500 EScv1 rose 0.47%.
While stocks have also rallied on the assumption that Democrat Joe Biden would be the next U.S. President, the top Republican in U.S. Congress on Monday did not acknowledge Biden as president-elect, raising concerns about a rough transition of
The Australian dollar
The yen
The vaccine news also sent long-dated U.S. Treasury yields sky-rocketing in their biggest one-day jump since March. The yield curve, an indication of risk appetite, hit its steepest level since March.
Bonds had their biggest selloff since recoiling from March peaks. The yield on benchmark 10-year U.S. government debt (US10YT=RR), which rises when prices fall, jumped 10.3 basis points on Monday and held above 0.9% on Tuesday at 0.9099%
The CBOE Market Volatility index (VIX), a barometer of investor anxiety, hit its lowest closing level since late August.
Oil prices lost momentum in Asian trade. Light crude oil (CLc1) fell by 1.49% to $39.74 a barrel while Brent crude (LCOc1) slipped 1.06%. [O/R]
Spot gold
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.